OncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients

OncoArendi Therapeutics SA today signed an agreement with VIB, one of the world leading life science research institutes. The scope of this research collaboration focuses on the role of chitinase and chitinase-like-proteins (CLPs) in COVID-19 and subsequent complication. This collaboration can lead to identification of new drug candidates that can alleviate COVID-19 complications, such as lung fibrosis.

Magda KućmaOncoArendi Therapeutics broadens its collaboration with VIB, a leading life science research institute in Europe, to investigate the role of chitinase family of proteins as potential therapeutic targets in COVID-19 patients
Czytaj więcej

OncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01

  •  the report confirms the OATD-01 safety profile which justifies further clinical development of this experimental drug
  • In Q1 of 2021 the company plans to file for an approval of the next phase clinical trial in sarcoidosis patients

OncoArendi Therapeutics S.A. (GPW: OAT) — a biotechnology company which specializes in discovery and development of new drugs will continue the clinical development of the OATD-01 molecule — an innovative small molecule chitinase inhibitor — in the treatment of severe pulmonary diseases such as sarcoidosis or idiopathic pulmonary fibrosis (IPF). OncoArendi Therapeutics is the first and so far only biotechnology company in the world, which conducts clinical trials of drug candidates targeting chitinase (first-in-class).

Magda KućmaOncoArendi Therapeutics has received the final report from the phase Ib clinical trial of innovative drug candidate OATD-01
Czytaj więcej

Dr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.

Dr. Zbigniew Zasłona, a biologist and scientist with impressive achievements in the area of pulmonary diseases (at Trinity College Dublin since 2015) has joined the research team of OncoArendi Therapeutics S.A. Prior to his collaboration with OncoArendi dr. Zasłona was a Senior Investigator at a biopharmaceutical company Sitryx, where he was responsible for studies on new therapeutic targets in the field of immunometabolism (development of anti-inflammatory medicines).

Magda KućmaDr. Zbigniew Zasłona joins OncoArendi Therapeutics as the new Director of the Biology Department. Dr Paweł Dobrzański, the current head of the Biology Department, will still be engaged in collaboration with OncoArendi as Senior Scientific Advisor on the company’s Scientific Advisory Board.
Czytaj więcej

Dr Timi Oshodi joined OncoArendi Therapeutics

OncoArendi Therapeutics – a biotechnology company specializing in the discovery, development and commercialization of innovative drugs, has hired Dr. Timi Oshodi as Director of Preclinical Development. Dr. Oshodi will be responsible for planning and implementing of preclinical safety and pharmacokinetic studies for molecules developed by the company.

Magda KućmaDr Timi Oshodi joined OncoArendi Therapeutics
Czytaj więcej

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship

A new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship, including case study of #OncoArendi Therapeutics authored by Marcin Szumowski

Magda KućmaA new series of publications about the future prospects and development of Polish biotechnology sector was released by Technology Transfer and Entrepreneurship
Czytaj więcej

OncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients

OncoArendi Therapeutics – a clinical stage biotechnology company specializing in the discovery and development of innovative small molecule drugs continues the clinical development of its first-in-class experimental drug candidate for treatment of sarcoidosis and idiopathic pulmonary fibrosis (IPF). OncoArendi Therapeutics is the first and thus far the only biotechnology company in the world conducting clinical research on new drugs blocking the activity of chitinase proteins.

OncoArendi Therapeutics announces the end of the clinical part of phase Ib trial (multiple ascending dose (MAD)) of the OATD-01 compound after confirming the tolerability of the tested doses and achieving the estimated pharmacodynamic effect. This was the second early phase clinical study after the successfully completed phase Ia “First in Human study” (single ascending dose – SAD).

Magda KućmaOncoArendi Therapeutics has completed a Phase Ib clinical trial with an innovative small molecule experimental drug – OATD-01. Further analyses of the data from the study will lead to the final report and advancing to phase II clinical trials in patients
Czytaj więcej

Drug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)

  • Potential effectiveness of OATD-01 in the treatment of pulmonary fibrosis is based on a unique mechanism of inhibiting a new biological target – chitotriosidase 1 (CHIT1)
  • Linking COVID-19 infection to pulmonary fibrosis where CHIT1 plays a role will increase the value of OATD-01 and other chitinase inhibitors for potential partners
Magda KućmaDrug Candidate OATD-01 may find use in treatment of pulmonary fibrosis in patients who have survived a new coronavirus infection (COVID-19)
Czytaj więcej

National Center for Research and Development (NCBR) funds OncoArendi Therapeutics’ new research platform of innovative anticancer drugs targeting deubiquitinase proteins.

A proposal submitted by OncoArendi Therapeutics in the Innovative Development Operational Programme (POIR) call for proposals for funding a research project – “RESEARCH AND DEVELOPMENT OF DEUBIQUITINASE INHIBITORS IN ANTITUMOR IMMUNOTHERAPY”, was recommended for funding in the official list published by the National Center for Research and Development (NCBR). The total budget of the project is approx. 31 million PLN, with the amount of funding over 22 million PLN.

Magda KućmaNational Center for Research and Development (NCBR) funds OncoArendi Therapeutics’ new research platform of innovative anticancer drugs targeting deubiquitinase proteins.
Czytaj więcej

New Head of Research (Chief Scientific Officer) at OncoArendi

OncoArendi has recently hired dr. Rafał Kamiński for the position of Chief Scientific Officer. He has acquired broad international experience in discovery and development of innovative small molecule drugs and management of scientific teams from previous work for global pharmaceutical companies. Immediately prior to accepting the CSO position at OncoArendi Therapeutics, dr. Kamiński worked for the Roche Group (Basel, Switzerland).

Magda KućmaNew Head of Research (Chief Scientific Officer) at OncoArendi
Czytaj więcej

First clinical proof-of-concept for arginase inhibitors in cancer immunotherapy

Data presented at the European Society of Medical Oncology (ESMO) in Barcelona by Calithera Biosciences, a biotechnology company from California, USA, add to a growing body of evidence indicating that arginase inhibitors could emerge as novel cancer immunotherapies.

A small molecule drug candidate (INCB001158), licensed by Calithera to Incyte Corporation, is the first arginase inhibitor currently in clinical development. On September 29th Calithera Biosciences presented results of a phase I clinical study of their small molecule drug candidate. In this safety and tolerability study, patients with metastatic or locally advanced cancers, not amendable to available therapies, were treated with INCB001158. Cancer types included lung cancer, colorectal cancer and other solid tumors. INCB1158 was well tolerated and inhibited plasma arginase activity, inducing increased plasma arginine levels at all doses tested.

Magda KućmaFirst clinical proof-of-concept for arginase inhibitors in cancer immunotherapy
Czytaj więcej